NBE-Therapeutics, a Switzerland-based company developing cancer therapies, has named Prof Dr Erich Schlick as independent chairman of its board of directors, it was reported on Monday.
Prof Schlick has more than 35 years' experience across the pharmaceutical and investment industry. Presently, he is the general partner and managing director at Wellington Partners. He has served as director and head of 3i Healthcare Germany and as deputy sector head of 3i Healthcare Worldwide. He has spent 15 years with BASF Pharma/Knoll AG where he was an executive board member with global responsibility for preclinical and clinical R&D.
Detlev Mennerich, partner at Boehringer Ingelheim Ventures and board member of NBE-Therapeutics, said, 'We are very pleased to welcome Prof Dr Erich Schlick to NBE-Therapeutics as chairman. His unrivalled experience and extensive network in the global life sciences industry will be invaluable to NBE-Therapeutics as it moves NBE-002, an anti-ROR1 Antibody Drug Conjugate through clinical development.'
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval